Enhancer-targeted genome editing selectively blocks innate resistance to oncokinase inhibition

Thousands of putative enhancers are characterized in the human genome, yet few have been shown to have a functional role in cancer progression. Inhibiting oncokinases, such as EGFR, ALK, ERBB2, and BRAF, is a mainstay of current cancer therapy but is hindered by innate drug resistance mediated by up...

Descripción completa

Detalles Bibliográficos
Autores principales: Webster, Dan E., Barajas, Brook, Bussat, Rose T., Yan, Karen J., Neela, Poornima H., Flockhart, Ross J., Kovalski, Joanna, Zehnder, Ashley, Khavari, Paul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009605/
https://www.ncbi.nlm.nih.gov/pubmed/24443471
http://dx.doi.org/10.1101/gr.166231.113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009605/
https://www.ncbi.nlm.nih.gov/pubmed/24443471
http://dx.doi.org/10.1101/gr.166231.113

Ejemplares similares